Program
Alendronate
Also written as “alendronate”, “Comparator: alendronate” and “Liposomal Alendronate”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Osteitis Deformans · Coronary Stenosis · Back Pain, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 90 open or running | phase 4since Aug 5, 2008 | Sep 21, 2004 | none ahead |
| Viatris | 20 open or running | phase 1since Sep 21, 2009 | Sep 21, 2009 | none ahead |
| BIOrest | 10 open or running | phase 2since Aug 20, 2008 | Aug 20, 2008 | none ahead |
| Dr. Reddy's Laboratories | 10 open or running | phase 1since May 27, 2010 | May 27, 2010 | none ahead |
| Evangelisches Krankenhaus Lutherhaus gGmbH | 10 open or running | phase 3since Jan 11, 2012 | Jan 11, 2012 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 4since May 18, 2006 | May 18, 2006 | none ahead |
| Radius Health | 10 open or running | phase 3since Jul 31, 2012 | Jul 31, 2012 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 21, 2004First studies: 3 phase 3 studies in Osteoporosis, PostmenopausalNew to OrganonOrganon · NCT00092040, NCT00092027, NCT00092014
- May 18, 2006GlaxoSmithKline's first study: phase 4 study in OsteoporosisNew to GlaxoSmithKlineGlaxoSmithKline · NCT00327990 · 300 enrolled · Netherlands
- Nov 10, 2006Phase 3 study in Osteoporosis, PostmenopausalOrganon · NCT00398931 · 1,099 enrolled
- May 30, 20072 phase 3 studiesOrganon · NCT00480766, NCT00480662
- Aug 5, 2008Phase 4 study in Osteoporosis, PostmenopausalOrganon · NCT00729651 · 343 enrolled
- Aug 20, 2008BIOrest's first study: phase 2 study in Coronary StenosisNew to BIOrestBIOrest · NCT00739466 · 226 enrolled · Israel
- Dec 4, 20082 phase 1 studies in OsteoporosisOrganon · NCT00803790, NCT00806416
- Jan 30, 2009Teva Pharmaceutical Industries's first study: phase 1 study in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00835406 · 140 enrolled · Canada
- Sep 21, 2009Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT01012934, NCT00983996
- May 27, 2010Dr. Reddy's Laboratories's first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01133496 · 80 enrolled · India
- Jan 11, 2012Evangelisches Krankenhaus Lutherhaus gGmbH's first study: phase 3 study in OsteoporosisNew to Evangelisches Krankenhaus Lutherhaus gGmbHEvangelisches Krankenhaus Lutherhaus gGmbH · NCT01512446 · 436 enrolled · Germany
- Jul 31, 2012Radius Health's first study: phase 3 study in Osteoporosis, PostmenopausalNew to Radius HealthRadius Health · NCT01657162 · 1,139 enrolled · United States, Argentina, Brazil and more
TargetBeta
“Farnesyl diphosphate synthase inhibitor”ChEMBL 37, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT01657162Osteoporosis, Postmenopausal · United States, Argentina, Brazil and more | 3 | Completed | Radius Health | Oct 3, 2016 | 1,139 |
| NCT01512446Osteoporosis · Germany | 3 | Terminated | Evangelisches Krankenhaus Lutherhaus gGmbH | Mar 2013 | 436 |
| NCT01133496Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Dec 2006 | 80 |
| NCT01012934Healthy · United States | 1 | Completed | Viatris | Aug 2002 | 110 |
| NCT00983996Healthy · United States | 1 | Completed | Viatris | Jul 2002 | 112 |
| NCT00835406Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2000 | 140 |
| NCT00806416Osteoporosis | 1 | Completed | Organon | Aug 2003 | 244 |
| NCT00803790Osteoporosis | 1 | Completed | Organon | Jul 2006 | 318 |
| NCT00739466Coronary Stenosis · Israel | 2 | Completed | BIOrest | Dec 2015 | 226 |
| NCT00729651Osteoporosis, Postmenopausal | 4 | Completed | Organon | Apr 10, 2009 | 343 |
| NCT00480766Osteoporosis | 3 | Completed | Organon | Aug 2003 | 173 |
| NCT00480662Osteitis Deformans | 3 | Completed | Organon | Oct 2002 | 60 |
| NCT00398931Osteoporosis, Postmenopausal | 3 | Completed | Organon | Oct 2003 | 1,099 |
| NCT00327990Osteoporosis · Netherlands | 4 | Completed | GlaxoSmithKline | Dec 2006 | 300 |
| NCT00092040Osteoporosis, Postmenopausal | 3 | Completed | Organon | Oct 18, 2004 | 936 |
| NCT00092027Osteoporosis, Postmenopausal | 3 | Completed | Organon | Mar 15, 2004 | 454 |
| NCT00092014Osteoporosis, Postmenopausal | 3 | Completed | Organon | Apr 1, 2004 | 1,053 |
How it is read
Names in the registry
- “Alendronate”, 7 entries
- “alendronate”, 2 entries
- “Comparator: alendronate”, 2 entries
- “Liposomal Alendronate”, 2 entries
- “Alendronate Sodium Tablets, 70 mg”, 2 entries
Codes read as this program: MK0217.
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 7 studies
- Osteoporosis, 6 studies
- Osteitis Deformans, 1 study
- Coronary Stenosis, 1 study
- Back Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.